Removed
Curious to get thoughts on the two. Comps / WLB / culture / performance / biz school placement. Old thread is a bit dated.
Trending Content - Private Equity Forum
| +24 | The Difference Between a Good Business and a Good Acquisition | 6 | 2h |
| +14 | Leave MF PE for FP&A Manager at Top Company? | 22 | 5h |
| +14 | Partners misalignmet common? | 4 | 1d |
| +13 | Career / Life Crossroads | 3 | 8h |
| +10 | How to prep for HH calls? | 3 | 3d |
| +9 | on-cycle possible after lateraling? | 1 | 2h |
| +9 | What to do - advice needed for incoming 27 associate | 2 | 12h |
| +7 | Stepstone PE Modeling Test | 3 | 3d |
| +7 | Wildcat (family office) - senior associate hiring | 1 | 4d |
| +6 | Opinions on DTCP? | 0 | 19h |
Career Resources
Bump
Bump
Bump
What ab permira / eqt / cvc as well as apax/bc
EQT just closed a $15b fund. Dunno about the others but I remembered reading that so at least fundraising isn’t a problem there
Following
BC has struggled to fundraise recently which is an indicator of performance. Something to consider
Interested on this… of course that seems likely and plausible… but looking at their last few funds, returns don't seem all that bad. By no means first quartile, but definitely stable right in the second quartile/better third quartile area at worst. Definitely a mix of being not top quartile and terrible fundraising environment, just not sure on the balance of those two factors.Also to note, maybe aside from a few (EQT, etc), I heard the fundraising environment for Euro buyout firms has been significantly more difficult than for US firms. Overall must seems just like a handful of headwinds (some being BC partners, others being external and somewhat uncontrollable).
BC was raising when everything was still going well and people were done in weeks / a few months. Part of the problem is that their returns are super concentrated in Chewy and hence replicability/sustainability of returns is a question
Nordic's fundraise seems to be going pretty well
Worth mentioning too that Nordic is one of the few savvy LBO shops that actually understands the life sci space, specifically spec pharma. Huge margins there if a buyer can find the right company with defensible assets against genericization and correctly invest capital into lifecycle management for existing commercial assets to extend the IP cliffs. I don't know a lick about their performance historically but can say confidently that they've had great success with that space and delivered excellent returns with their spec pharma plays so if that influenced anything on their fundraise, I wouldn't be surprised.
Any insight on comp/WLB?
Eligendi ea iure aperiam reiciendis aut. Assumenda et accusamus eos quis similique. Ipsam vero sunt dolorem est vel voluptatem porro. Ea eaque quia eos maxime qui eius. Quo dolorem incidunt vel voluptate et odit fugiat.
Eaque expedita placeat dolorum perferendis tempora dolorem. Excepturi sunt dolor doloribus inventore illo debitis nihil. Et totam et voluptatibus porro velit sint. Necessitatibus asperiores quasi labore velit consequatur iusto optio. Ea accusantium quis eligendi culpa.
Praesentium qui quidem pariatur ea repudiandae quia aspernatur. Et quo quo error nulla consequatur ad. Quos ratione expedita nostrum dicta repellat vel aspernatur odit. Minus odio rerum quis rerum debitis itaque magnam. Non accusamus reiciendis ab quia. Iste corporis ad voluptatem.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...